Review: Long-acting insulin analogues reduce risk for hypoglycemia compared with NPH insulin in type 2 diabetes: COMMENTARY

Pugh, Jacqueline
September 2007
ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p46
Academic Journal
The article presents the author's views on the review of a research by K. Horvath and colleagues that suggested that long-acting insulin analogues reduce risk for hypoglycemia compared with human isopane (NPH) insulin in patients with type 2 diabetes. It is viewed that interpretation of reported hypoglycemia is difficult due to lack of blinding to treatment type and subjective definitions of hypoglycemia. It is stated that compared to NPH, long-acting insulin analogues are costly also.


Related Articles

  • Review: Long-acting insulin analogues reduce risk for hypoglycemia compared with NPH insulin in type 2 diabetes.  // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p46 

    The article presents information on a research that suggested that long-acting insulin analogues reduce risk for hypoglycemia compared with human isopane (NPH) insulin in patients with type 2 diabetes. The research found that detemir reduced risks for overall and nocturnal hypoglycemia while...

  • MannKind's inhaled insulin meets Phase III trials' goals. YOUNG, DONNA // Medical Device Daily;12/8/2008, Vol. 12 Issue 237, p1 

    The article reports on the statement issued by MannKind that the final two pivotal Phase III studies of its rapid-acting inhaled insulin drug Afresa met their primary endpoints in patients with Type 1 and Type 2 diabetes. Data released from studies 030 and 102 follows results released earlier...

  • Análisis de costo-utilidad del uso de detemir en pacientes con diabetes tipo 2. Romero-Prada, Martín Emilio; Huérfano-Rey, Lina María; Páez, Mary Luz; Acero-Acero, Germán; Alfonso-Quiñones, Pamela Andrea // Revista Gerencia y Políticas de Salud;ene-jun2015, Vol. 14 Issue 28, p190 

    Objective: Performing a cost-utility analysis to assess the treatment with different insulin options in patients with Type 2 Diabetes. Methodology: Based on the analysis previously performed by Romero et al., we updated the information and included an specific analysis for the quality of life....

  • COMMENTARY: Review: Meglitinide analogues reduce glucose levels in type 2 diabetes, but morbidity and mortality effects are unknown. Ganda, Om P. // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p65 

    The author reflects upon the results of a clinical study on the effectiveness and safety of meglitinide analogues (MA) in the treatment of type 2 diabetes mellitus. He comments that the MAs improved the glycemic control but the efficacy of MAs and sulfonylureas was not compared in the study. He...

  • Exenatide trumps insulin glargine in cost effectiveness.  // PharmacoEconomics & Outcomes News;9/5/2009, Issue 586, p1 

    The article discusses research being done on the cost effectiveness of exenatide for treating certain type 2 diabetes mellitus patients in Switzerland. It references the study "Exenatide Versus Insulin Glargine: A Cost-Effectiveness Evaluation in Patients With Type 2 Diabetes in Switzerland," by...

  • Optimizing the Treatment of Type 2 Diabetes Using Current and Future Insulin Technologies. Boyle, Mary E. // MEDSURG Nursing;Dec2008, Vol. 17 Issue 6, p383 

    The article reports on the optimization of treating type 2 diabetes using insulin analogs. The development of new insulin analogs and modern delivery devices makes optimal glycemic control more achievable because they can closely mimic the effect of endogenous insulin. These advances also demand...

  • Insulin.  // Reactions Weekly;10/24/2009, Issue 1275, p20 

    The article describes the case of six patients who acquired type 1 diabetes mellitus (T1DM) while undergoing treatment with insulin for type 2 diabetes mellitus (T2DM). The patients, four men and two women with an average age of 42.6 years, first developed insulin deficiency. One patient was...

  • For Treatment of Type 2 Diabetes, Complete Lack of Coverage of GLP-1 Analogues by Government-Sponsored Programs in Brazil, and Limited Coverage in Mexico, Substantially Restricts Prescribing of These Agents in the Public Setting.  // Biomedical Market Newsletter;8/22/2012, Vol. 21, p1 

    The article focuses on a report from Decision Resources Inc. which found limited coverage of injectable type II diabetes therapies by public programs for pharmaceutical assistance in Brazil and in Mexico. It mentions that GLP-1 analogue prescribing is uncommon in the public setting in both...

  • Treatment of type II diabetes. Nattrass, Malcolm // British Medical Journal (Clinical Research Edition);4/19/1986, Vol. 292 Issue 6527, p1033 

    Focuses on the clinical management of type II diabetes. Mechanism of action of sulphonylureas; Shift from long to a short acting drug among older patients; Control of hypoglycemia by administering oral hypoglycemic agents.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics